Abstract:Background: The aggregation and spread of misfolded amyloid structured proteins, such as tau and α-synuclein, are key pathological features associated with neurodegenerative disorders, including Alzheimer's and Parkinson's disease. These proteins possess a prion-like property, enabling their transmission from cell to cell leading to propagation throughout the central and peripheral nervous systems. While the mechanisms underlying their intracellular spread are still being elucidated, targeting the extracellular space has emerged as a potential therapeutic approach. The glymphatic system, a brain-wide pathway responsible for clearing extracellular metabolic waste from the central nervous system, has gained attention as a promising target for removing these toxic proteins. Methods: In this study, we investigated the impact of long-term modulation of glymphatic function on tau aggregation and spread by chronically treating a mouse model of tau propagation with a pharmacological inhibitor of AQP4, TGN-020. Thy1-hTau.P301S mice were intracerebrally inoculated with tau into the hippocampus and overlying cortex, and subsequently treated with TGN-020 (3 doses/week, 50 mg/kg TGN-020, i.p.) for 10-weeks. During this time, animal memory was studied using cognitive behavioural tasks, and structural MR images were acquired of the brain in vivo prior to brain extraction for immunohistochemical characterisation. Results: Our findings demonstrate increased tau aggregation in the brain and transhemispheric propagation in the hippocampus following the inhibition of glymphatic clearance. Moreover, disruption of the glymphatic system aggravated recognition memory in tau inoculated mice and exacerbated regional changes in brain volume detected in the model. When initiation of drug treatment was delayed for several weeks post-inoculation, the alterations were attenuated. Conclusions: These results indicate that by modulating AQP4 function and, consequently, glymphatic clearance, it is possible to modify the propagation and pathological impact of tau in the brain, particularly during the initial stages of the disease. These findings highlight the critical role of the glymphatic system in preserving healthy brain homeostasis and offer valuable insights into the therapeutic implications of targeting this system for managing neurodegenerative diseases characterized by protein aggregation and spread.

Disruption of tubulin-alpha4a polyglutamylation prevents aggregation of hyper-phosphorylated tau and microglia activation in mice

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Effects of P301L-TAU on post-translational modifications of microtubules in human iPSC-derived cortical neurons and TAU transgenic mice

The Distinct Initiation Sites and Processing Activities of TTLL4 and TTLL7 in Glutamylation of Brain Tubulin.

Knockdown of TTLL1 reduces Aβ-induced TAU pathology in human iPSC-derived cortical neurons

Antibody-mediated degradation of 4R-tau restores mitochondrial membrane polarization in human induced pluripotent stem cell-derived neurons with the MAPT 10+16 mutation

O-GlcNAcylation Modulates the Self-Aggregation Ability of the Fourth Microtubule-Binding Repeat of Tau

Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent inflammatory responses

Expression of recombinant human glutamylating TTLLs in human cells leads to differential tubulin glutamylation patterns, with only TTLL6 disrupting microtubule dynamics

Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses

Aggregation promoting sequences rather than phosphorylation are essential for Tau-mediated toxicity in

Glymphatic inhibition exacerbates tau propagation in an Alzheimer's disease model

Near-atomic model of microtubule-tau interactions

Phosphorylation and O-GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates

Therapeutic suppression of Tubb4a rescues H-ABC leukodystrophy

Identification of Stk25 as a genetic modifier of Tau phosphorylation in Dab1-mutant mice

A Unique Tau Conformation Generated by an Acetylation-Mimic Substitution Modulates P301S-dependent Tau Pathology and Hyperphosphorylation.

Rescue of synaptosomal glutamate release defects in tau transgenic mice by the tau aggregation inhibitor hydromethylthionine

Dual Modification of Tau by Pseudophosphorylation and Glycation Does Not Enhance Amorphous Aggregation

Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP

Clearing truncated tau protein restores neuronal function and prevents microglia activation in tauopathy mice